# US 2012/0252798 A1 · Indole compounds as an inhibitor of cellular necrosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252798 A1
- Document ID: US20120252798A1
- Status: Published application
- Kind: A1
- Application number: 13/493,045
- Filed: 2012-06-11
- Published: 2012-10-04
- Earliest claimed: 2007-08-17
- Assignees: LG Life Sciences Ltd.
- Inventors: Soon Ha KIM; Hyoung Jin Kim; Sun Young Koo; Sung Bae Lee; Heui Sul Park; Seung Hyun Yoon; Seung Yup Paek; Hyo Shin Kwak; Dong Ook Seo; Eok Park
- Web page: https://patentgrep.com/patent/US20120252798A1

## CPC

- C07D 417/06: linked by a carbon chain containing only aliphatic carbon atoms
- A61K 31/404: Indoles, e.g. pindolol
- A61K 31/416: condensed with carbocyclic ring systems, e.g. indazole
- A61K 31/427: not condensed and containing further heterocyclic rings
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/445: Non condensed piperidines, e.g. piperocaine
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 31/4545: containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/497: containing further heterocyclic rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/541: Non-condensed thiazines containing further heterocyclic rings
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/14: Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/38: of the suprarenal hormones
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 9/14: Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/16: Central respiratory analeptics
- A61P 13/00: Drugs for disorders of the urinary system
- A61P 13/12: of the kidneys
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 17/06: Antipsoriatics
- A61P 17/16: Emollients or protectives, e.g. against radiation
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 21/04: for myasthenia gravis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 25/30: for treating abuse or dependence
- A61P 25/32: Alcohol-abuse
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 31/06: for tuberculosis
- A61P 31/12: Antivirals
- A61P 33/02: Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 39/02: Antidotes
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 413/04: directly linked by a ring-member-to-ring-member bond
- C07D 413/14: containing three or more hetero rings
- C07D 417/04: directly linked by a ring-member-to-ring-member bond
- C07D 417/14: containing three or more hetero rings
- C07D 487/04: Ortho-condensed systems
- C07F 9/65583: {each of the hetero rings containing nitrogen as ring hetero atom}
- C07F 9/65586: {at least one of the hetero rings does not contain nitrogen as ring hetero atom}
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)

## Abstract

The present invention relates to new indole compounds, pharmaceutically acceptable salts or isomers thereof which are useful for the prevention or treatment of cellular necrosis and necrosis-associated diseases. The present invention also relates to a method and a composition for the prevention or treatment of cellular necrosis and necrosis-associated diseases, comprising said indole compounds as an active ingredient.

## Claims

### Claim 1

A method for the treatment of necrosis and necrosis-associated diseases comprising administering a composition which comprises an indole compound of the following formula (1), pharmaceutically acceptable salt or stereoisomer thereof as an active ingredient together with a pharmaceutically acceptable carrier or diluent to a subject in need thereof:
in which
n denotes a number of 0 to 3,
A represents 5 membered heteroaryl or heterocycle each of which has 1 to 3 hetero atoms selected from N, O and S,
R1 represents R5—X—B—X′—,
B represents a direct bond, or represents 3˜10 membered heterocycle or heteroaryl each of which has 1 to 4 hetero atoms selected from N, O and S,
X and X′ independently of one another represent a direct bond, or are selected from the group consisting of —NR6—, —CO—, —CONR6—, —CO2—, —OC(O)—, —S(O)m—, —O—(CH2)m—, —(CH2)m—O—, —(CH2)m—, —NR6CO—, —(R6O)2P(O)— and —NHCO2—, wherein m denotes a number of 0 to 3, and R6 represents hydrogen or alkyl,
R5 represents hydrogen, hydroxy, alkyl, alkoxy, cycloalkyl or 4˜10 membered aryl, or represents 3˜10 membered monocyclic or fused cyclic heterocycle or heteroaryl each of which has 1 to 3 hetero atoms selected from N, O and S, and is optionally substituted by oxo or alkyl, or
R2 represents —(CR8R9)p—Y—R7,
p denotes a number of 0 to 2,
R8 and R9 independently of one another represent hydrogen or alkyl,
Y represents a direct bond, or is selected from the group consisting of —O—, —S—, —NR6—, —NR6C(O)—, —C(O)NR6— and —S(O)q—, wherein q denotes a number of 0 to 2,
R7 represents hydrogen, halogen, hydroxy, alkyl, 4˜10 membered aryl, or represents 3˜10 membered heterocycle or heteroaryl each of which has 1 to 3 hetero atoms selected from N, S and O and which optionally contains oxo,
R3 represents hydrogen, alkyl, or —(CH2)q-cycloalkyl,
R4 represents cycloalkyl,
where alkyl, alkoxy, aryl, cycloalkyl, heterocycle and heteroaryl may be optionally substituted, and the substituents are one or more selected from the group consisting of hydroxy, halogen, nitrile, amino, alkylamino, dialkylamino, alkyl, haloalkyl, alkylsulfonyl, carboxyalkyl, alkylcarbonyloxy, alkylthio, alkyloxycarbonyl, alkylaminocarbonyl, arylalkoxy and oxo.

### Claim 2 (depends on 1)

The method of claim 1, wherein necrosis and necrosis-associated diseases are selected from the group consisting of acute/chronic hepatic disease, neurodegenerative disease, ischemic disease, diabetes, pancreatitis, bacterial/viral sepsis, necrotizing procolitis, cystic fibrosis, rheumatoid arthritis, degenerative arthritis, nephropathy, bacterial infection, viral infection, multiple sclerosis, leukemia, lymphoma, neonatal respiratory distress syndrome, asphyxia, tuberculosis, endometriosis, angiasthenia, psoriasis, chilblain, steroid treatment complications, gangrene, pressure sores, hemoglobinuria, burns, hyperthermia, Crohn's disease, celiac disease, compartment syndrome, spiral cord injury, glomerulonephritis, muscular dystrophy, metabolic inherited disease, mycoplasmal disease, anthrax, Andersen's disease, congenital mitochondrial disease, phenylketonuria, placental infarction, syphilis, and aseptic necrosis.

### Claim 3 (depends on 1)

The method of claim 1, wherein necrosis and necrosis-associated diseases are caused by drugs and toxic substances and are selected from the group consisting of the necrosis associated with alcoholism, the exposure to, or administration or self-administration of, cocaine, drugs, antibiotics, anti-cancer agent, adriamycin, puromycin, bleomycin, NSAID, cyclosporine, chemical toxins, poison gas, agrochemicals, heavy metals, or injury due to the exposure to radioactivity/UV and associated necrosis thereof.

### Claim 4 (depends on 1)

The method of claim 1, which is for hepatoprotection, hepatic functional improvement, and treatment of hepatic disease.

### Claim 5 (depends on 4)

The method of claim 4, wherein the hepatic disease is selected from the group consisting of liver transplantation, alcoholic or non-alcoholic fatty liver, hepatic fibrosis, hepatocirrhoisis and hepatitis caused by virus or drugs.

### Claim 6 (depends on 4)

The method of claim 4, wherein the hepatic disease is alcoholic acute/chronic hepatic disease.

### Claim 7 (depends on 4)

The method of claim 4, wherein the hepatic disease is fatty acid-induced fatty liver or acute/chronic hepatic disease derived from fatty liver.

### Claim 8 (depends on 4)

The method of claim 4, wherein the hepatic disease is mediated by reactive oxygen species (ROS).

### Claim 9 (depends on 4)

The method of claim 4, wherein the hepatic disease is mediated by heavy metals.

### Claim 10 (depends on 1)

The method of claim 1, wherein a prophylactic or therapeutic agent for drug-derived necrosis and necrosis-associated diseases is co-administered.

### Claim 11 (depends on 10)

The method of claim 10, wherein the prophylactic or therapeutic agent for drug-derived necrosis and necrosis-associated diseases is selected from the group consisting of antibiotics, anti-cancer agents, anti-viral agents, anti-infectives, anti-inflammatory agents, anti-coagulants, lipid-improving agents, cell death inhibitors, anti-hypertensive agents, anti-diabetic/anti-obesity agents, therapeutic agents for cardiovascular disease, therapeutic agents for neurodegenerative disease, anti-aging agents, and therapeutic agents for metabolic disease.

### Claim 12 (depends on 4)

The method of claim 4, wherein an agent selected from the group consisting of hepatocyte regeneration promoters, hepatic functional adjuvants, anti-viral agents, immunosuppressants, and fibrosis inhibitors is co-administered.

### Claim 13 (depends on 2)

The method of claim 2, wherein the neurodegenerative disease is dementia, Parkinson's disease, or Huntington's disease.

### Claim 14 (depends on 2)

The method of claim 2, wherein the ischemic disease is cardiac disease, reperfusion injury, ischemic stroke, or ischemic injury.

### Claim 15 (depends on 2)

The method of claim 2, wherein the diabetes is caused by pancreatic cell destroying substances, diabetic complications, or diabetic vascular disease.

### Claim 16 (depends on 15)

The method of claim 15, wherein the diabetes is mediated by virus, hyperglycemia, fatty acid, diet, toxin, or streptozotocin.

### Claim 17 (depends on 1)

A method of preparing a composition for the prevention or treatment of necrosis and necrosis-associated diseases, which comprises mixing the compounds of formula (1), pharmaceutically acceptable salts or isomers thereof as defined in claim 1 as an active ingredient together with pharmaceutically acceptable carrier.
